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Abstract
Background: Coeliac disease (CD) is an enteropathy characterized by an aberrant immune
response to cereal-gluten proteins. Although gluten peptides and microorganisms activate similar
pro-inflammatory pathways, the role the intestinal microbiota may play in this disorder is unknown.
The purpose of this study was to assess whether the faecal microbiota of coeliac patients could
contribute to the pro-inflammatory milieu characteristic of CD and the possible benefits of
bifidobacteria.
Methods: The effect of faeces of 26 CD patients with active disease (mean age 5.5 years, range
2.1–12.0 years), 18 symptom-free coeliac disease (SFCD) patients (mean age 5.5 years, range 1.0–
12.3 years) on a gluten-free diet for 1–2 years; and 20 healthy children (mean age 5.3 years, range
1.8–10.8 years) on induction of cytokine production and surface antigen expression in peripheral
blood mononuclear cells (PBMCs) were determined. The possible regulatory roles of
Bifidobacterium longum ES1 and B. bifidum ES2 co-incubated with faecal samples were also assessed
in vitro.
Results: Faeces of both active CD and SFCD patients, representing an imbalanced microbiota,
significantly increased TNF-α production and CD86 expression in PBMCs, while decreased IL-10
cytokine production and CD4 expression compared with control samples. Active CD-patient
samples also induced significantly higher IFN-γ production compared with controls. However,
Bifidobacterium strains suppressed the pro-inflammatory cytokine pattern induced by the large
intestinal content of CD patients and increased IL-10 production. Cytokine effects induced by
faecal microbiota seemed to be mediated by the NFκB pathway.
Conclusion:  The intestinal microbiota of CD patients could contribute to the Th1 pro-
inflammatory milieu characteristic of the disease, while B. longum ES1 and B. bifidum ES2 could
reverse these deleterious effects. These findings hold future perspectives of interest in CD therapy.
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Background
Coeliac disease (CD) is an enteropathy characterized by
an aberrant immune response to ingested wheat-gluten
proteins (gliadins) and related prolamins of rye and bar-
ley, occurring in genetically predisposed (HLA-DQ2/
DQ8) individuals. The pathogenesis of CD involves inter-
action with genetic, immunological and environmental
factors. HLA-DQ2/DQ8 molecules of antigen-presenting
cells bind and present gluten peptides to lamina propria
CD4+ T cells, triggering a T helper 1 (Th1) biased immune
response, mainly with interferon gamma (IFN-γ) produc-
tion, which enhances tumour necrosis factor alpha (TNF-
α) production and plays a crucial role in damaging the
intestinal mucosa [1,2]. In addition, events leading to CD
involve activation of innate immunity mediated by inter-
leukin (IL)-15, and are characterized by expansion of
intraepithelial TCRγ/δ + and CD+8 TCRα/β + lym-
phocytes, which are cytotoxic for epithelial cells and also
contribute to tissue damage [3]. The intestinal inflamma-
tory milieu characteristic of CD patients depends on the
pro-inflammatory cytokines produced during abnormal
response to gluten, involving several intracellular signal
transduction pathways, such as nuclear factor kappa (NF-
κ) B, the interferon regulatory factor (IRF)-1 and signal
transducer and activator of transcription [4-6]. NFκB
pathway is a crucial target in the propagation of inflam-
matory responses triggered by cytokines (TNF-α and IFN-
γ) and microbial pathogens recognised by Toll-like recep-
tors located in intestinal epithelial and innate immune
cells [7]. IκB, a strong regulator of NFκB, is induced by
lypopolysaccharide of Gram-negative bacteria, as well as
by TNF-α, leading to transcription of genes that contribute
to the inflammatory process. Type I interferon IRF-α,
which is a cytokine produce by infected cells through the
NFκB pathway, induces IFN-γ production and thereby
IRF-1 expression, promoting a Th1 response in the CD
small intestinal mucosa [4,8]. Increased production of
pro-inflammatory cytokines by cells of the innate
immune system could also favour the recruitment of lym-
phocytes into the lamina propria and epithelium, contrib-
uting to full expression of the disease [6]. These
pathological mechanisms lead to typical CD lesions, char-
acterized by a massive intraepithelial infiltration of lym-
phocytes, crypt hyperplasia and villous atrophy [1].
Although CD is considered to be the commonest lifelong
digestive disorder, the only therapeutic alternative availa-
ble for CD patients is adherence to a strict gluten-free diet.
Poor compliance and associated complications of the dis-
ease demand alternative therapeutic strategies.
There is a lack of research into the role of the intestinal
microbiota in CD [9] despite the fact gliadin peptides and
microorganisms seem to activate similar pro-inflamma-
tory pathways. There have been recent reports of altera-
tions in the composition of the faecal and duodenal
microbiota of CD children in comparison with healthy
controls [10,11]. Bifidobacterium populations were signifi-
cantly lower in faecal samples of active CD children and
also tended to be lower in biopsies when compared with
control subjects ([11], Nadal, Medina, Donat, Ribes-Kon-
inckx, Calabuig & Sanz, unpublished). Specific Bifidobac-
terium  strains have been acknowledged for their anti-
inflammatory and regulatory properties by inducing IL-10
production and regulating the Th1/Th2 balance [12,13].
This has led to certain strains being proposed for use as
probiotics, to treat or prevent chronic inflammatory con-
ditions like inflammatory bowel diseases but not CD
[9,14].
The aim of the present work was to assess whether altera-
tions in microbiota of the large intestine, corresponding
to children with active and non-active CD, could contrib-
ute to activate immune responses and induce the pro-
inflammatory milieu associated with CD in vitro using
peripheral blood-mononuclear-cells. In addition, the
potential role that selected Bifidobacterium strains can play
in suppressing the intestinal pro-inflammatory milieu
common to these patients was evaluated, as well as their
possible mechanism of action.
Methods
Subjects and faecal sampling
Altogether 64 children were included in the study: 26 CD
patients with active disease (mean age 5.5 years, range
2.1–12.0 years) on a normal gluten-containing diet, 18
symptom-free coeliac disease (SFCD) patients (mean age
5.5 years, range 1.0–12.3 years) on a gluten-free diet for
1–2 years, and 20 healthy children (mean age 5.3 years,
range 1.8–10.8 years) without known food intolerance.
CD was diagnosed on the basis of clinical symptoms, pos-
itive serology markers (antigliadin and antitransglutami-
nase antibodies) and signs of severe enteropathy by
duodenal biopsy examination and positive response to a
gluten-free diet. SFCD patients showed negative serology
markers and normal duodenal mucosal villous architec-
ture. The children included in the study were not treated
with antibiotics for at least one month before the sam-
pling time. The study was conducted in accordance with
the ethical rules of the Helsinki Declaration (Hong Kong
revision, September 1989), following the EEC Good Clin-
ical Practice guidelines (document 111/3976/88 of July
1990) and current Spanish law which regulates clinical
research in humans (Royal Decree 561/1993 regarding
clinical trials). Children were enrolled in the study after
written informed consent obtained from their parents.
Faecal samples were collected from the three groups of
children under study (2 g wet weight), diluted 10-fold in
phosphate-buffered saline (PBS, 130 mM sodium chlo-
ride, 10 mM sodium phosphate, [pH 7.2]) and homoge-Journal of Inflammation 2008, 5:19 http://www.journal-inflammation.com/content/5/1/19
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nized in a Lab Blender 400 stomacher for 3 min (Seward
Medical London, UK). Aliquots of this dilution were kept
at -80°C for further immunologic studies.
Bacterial strains and culture conditions
The strains Bifidobacterium longum ES1 (CECT 7347) and
Bifidobacterium bifidum ES2 (CECT 7365) used in the
present study were isolated from faeces of healthy babies
under breast-milk feeding as described elsewhere [15].
Bifidobacteria were identified at species level by partial
sequencing of the 16S rRNA gene amplified with the
primers Y1 and 1401R for B. longum ES1 and 27F and
1401R for B. bifidum ES2 [16,17] and the tuf gene ampli-
fied with primers BIF-1 and BIF-2 as described elsewhere
[18]. Additional primers (27f, Y1, 530f and U-968f) were
used for sequencing in an ADN ABI 3700 automated
sequencer (Applied Biosystem, Foster City, CA).
Strains were routinely grown in de Man, Rogosa and
Sharpe (MRS) broth (Scharlau Chemie S.A., Barcelona,
Spain) supplemented with 0.05% (w/v) cysteine (Sigma,
St. Louis, MO) (MRS-C) and incubated at 37°C under
anaerobic conditions (AnaeroGen; Oxoid, Basingstoke,
UK) for 22 h. Cells were harvested by centrifugation
(6,000 g for 15 min) during stationary growth phase,
washed twice in phosphate buffered saline (PBS, 130 mM
sodium chloride, 10 mM sodium phosphate, pH 7.4), and
re-suspended in PBS containing 20% glycerol. Aliquots of
these suspensions were frozen in liquid nitrogen and
stored at -80°C until used. The number of live cells after
freezing and thawing was determined by colony-forming
unit (CFU) counting on MRS-C agar after 48 h incubation.
These constituted the live-cell suspensions used in co-
stimulating assays. For all strains tested, more than 90%
cells were alive upon thawing and no significant differ-
ences were found during storage time (4 months). One
fresh aliquot was thawed for every new experiment to
avoid variability in the cultures between experiments.
Isolation and stimulation of peripheral blood mononuclear 
cells
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from heparinized peripheral blood of four healthy
volunteers (median age 30 years, range 24–40 years) as
previously described [12]. Briefly, PBMCs were isolated by
centrifugation over a Ficoll density gradient (Amersham
Biosciences, Piscataway, NJ), and adjusted to 1 × 106 cells/
ml in RPMI 1640 (Cambrex, New York, USA), supple-
mented with 10% foetal bovine serum (FBS) (Gibco, Bar-
celona, Spain), 2 mM L-glutamine, 100 μg/ml
streptomycin and 100 U/ml penicillin (Sigma). PBMCs
were incubated in 24-well flat-bottom polystyrene micro-
titre plates (Corning, Madrid, Spain) and stimulated by
either faeces (30 μl), bifidobacterial cell suspensions (106
CFU/ml) or their combination, at 37°C under 5% CO2 for
24 h. Bifidobacterial cell suspensions were washed and re-
suspended in fresh PBS prior use for PBMC stimulation.
Bacterial growth was not detected during co-incubation of
neither faeces or bifidobacterial cell suspensions with
PBMCs as determined by colony-forming unit (CFU)
counting on Wilkins-Chalgren agar for quantification of
total anaerobs (Oxoid, Hampshire, England) and MRS-C
agar. Purified lipopolysaccharide (LPS) from E. coli
O111:B4 (Sigma, St. Louis, MO) was used at a concentra-
tion of 1 μg/ml as a positive control. Non-stimulated
PBMCs were also evaluated as controls of basal cytokine
production and cell-surface marker expression. To investi-
gate the possible involvement of the NK-κB pathway on
the immune effects of faeces and bifidobacteria the stim-
ulation of PBMCs was also carried out in the presence of
20 μg/ml lactacystin (Sigma, St. Louis, MO), which is a
specific inhibitor of this pathway. All reagents were tested
by the E-toxate test for LPS (Sigma) and shown to be
below the detection limit (2 pg/ml). Every fraction used as
stimulant was assayed in duplicate. Cell-culture superna-
tants were collected by centrifugation, fractionated in aliq-
uots, and stored at -20°C until cytokines were analysed.
Cytokine determinations by enzyme-linked 
immunosorbent assay (ELISA)
Cytokine concentrations of supernatants were measured
by ELISA using the Ready SET Go! Kit (BD-Bioscience, San
Diego, CA). The pro-inflammatory cytokines TNF-α and
INF-γ and the regulatory cytokine IL-10 were analysed.
The detection procedures were according to the manufac-
turer's instructions. The sensitivity of assays for each
cytokine was as follows: 4 pg/ml for IFN-γ and TNF-α, and
2 pg/ml for IL-10.
PBMC surface phenotyping and flow cytometric analyses
To evaluate the effects of the faeces, bifidobacterial sus-
pensions and the combination of both on PBMC surface
antigen expression, cells of 1 ml well-culture were
removed by scraping and incubated with FITC-labelled
anti-human CD4, CD8 and CD86 antibodies for 30 min,
according to the manufacturer's instructions (eBioscience,
San Diego, CA). Then, cells were washed twice, re-sus-
pended in ice-cold PBS and analyzed by flow cytometry
on EPICS® XL-MCL flow cytometer (Beckman Coulter,
Florida), setting the 0.22 μl filter that eliminates bacteria.
Data were analyzed with the System II V.3 software (Beck-
man Coulter, Florida). Every sample was assayed in dupli-
cate.
Statistical analyses
Statistical analyses were carried out with Statgraphics plus
5.1 software (Manugistics, Rockville, MD, USA). Signifi-
cant differences between means were established by
ANOVA with post hoc Fisher's least significant difference
(LSD) test at P < 0.05. Data are expressed as mean andJournal of Inflammation 2008, 5:19 http://www.journal-inflammation.com/content/5/1/19
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standard deviation (SD) of duplicate measures deter-
mined in four independent experiments.
Results and discussion
Cytokine patterns induced by faeces of CD patients on 
PBMCs
The cytokine production patterns induced by faeces of
active CD patients, SFCD patients and age-matched con-
trols in PBMCs are shown in Fig. 1. TNF-α production was
significantly higher when cells were stimulated with faeces
from both active and SFCD patients as compared to con-
trols (P < 0.001; Fig 1A). IFN-γ production was also signif-
icantly higher when cells were stimulated with faeces of
active CD patients than with those of healthy controls (P
< 0.001; Fig 1B). By contrast, faeces of healthy controls
induced significantly higher IL-10 production than those
of active CD patients and, particularly, of SFCD patients
(P < 0.050; Fig. 1C). Therefore, the immunostimulating
effects of faeces of CD patients produced a pro-inflamma-
tory milieu similar to that associated with this disorder,
characterized by an increase in IFN-γ and TNF-α produc-
tion and deficient counter-regulatory mechanisms [2,19].
A Th1 response dominated by high levels of IFN-γ has
been reported in the small intestine of untreated CD
patients and in the mucosa of treated patients, following
culture in vitro with gliadin [20] as well as in intraepithe-
lial lymphocytes isolated from untreated coeliac mucosal
samples [19,21]. Previously detected differences in the
microbiota structure between CD patients and healthy
controls could be responsible for the production of the
cytokine pattern characteristic of the disease (Nadal et al.,
unpublished). It has been estimated that bacterial compo-
nents constitute a major percentage (more than 50%) of
faecal solids, representing one of the main bioactive com-
pounds given the high intestinal bacterial numbers
reached in the colon (1011–1012 CFU per gram of faeces)
[22]. In addition, microbial-derived metabolites could
contribute indirectly to the detected immunostimulating
effects of faeces [23]. In particular, the microbiota of
active CD patients was characterized by a significant
decrease in the proportions of total Gram-positive bacte-
ria and Bifidobacterium, and an increase in Bacteroides
when compared with SFCD patients and controls. CD
patients with active and inactive disease also showed
lower ratios of Gram-positive to Gram-negative bacteria
when compared with healthy controls (Nadal et al.,
unpublished). Bifidobacterium strains have generally been
regarded as anti-inflammatory and beneficial gut
microbes, whereas certain species of Bacteroides have been
shown to trigger inflammation involved in chronic
inflammatory bowel diseases [24,25]. In the case of CD, it
has been suggested that infections, as well as the over-
growth of opportunistic pathogens, may initiate or con-
tribute to the pathological process by increasing the
production of inflammatory mediators. Such mediators
include TNF-α and IFN-γ, which are known to increase
permeability and could, in turn, favour the access of
higher antigen loads (gliadin and microbial) to the sub-
mucosa [9]. Furthermore, increased production of pro-
inflammatory cytokines like TNF-α and IL-8 through acti-
vation of cells of the innate immune system (monocytes,
macrophages and dendritic cells) is thought to contribute
to the pathogenesis of the disease by promoting lym-
phocyte recruitment into the lamina propria [6]. IFN-γ
could also be involved in T-lymphocyte recruitment and
exert an additive effect to that of TNF-α on T-cell migra-
tion [26,27]. In addition, IFN-γ has been shown to exert a
synergic effect with gliadin peptides, inducing activation
of blood monocytes and increasing TNF-α production [6].
Therefore, both the imbalanced gut microbiota and glia-
dins could exert a synergistic effect and stimulate the
release of pro-inflammatory cytokines from mucosa
innate immune cells, thus contributing to the recruitment
of T cells to the submucosa and the full expression of the
disease [6,9]. The lower induction of IL-10 production
stimulated by faeces of active CD and SFCD patients may
also reflect a defect in their ability to counteract the pro-
inflammatory responses resulting from alterations in their
intestinal microbiota, in addition to those derived from
genetic factors [19]. SFCD patients' faeces induce lower IL-
10 production, even after following a long-term gluten-
free diet. This indicates that these individuals are also
more prone to immune dysregulation against a noxious
stimulus than age-matched healthy subjects due to
changes in the intestinal ecosystem. Increased levels of
both IL-10 and IFN-γ have been reported in small intesti-
nal biopsies and intraepithelial lymphocytes isolated
from untreated coeliac mucosa [19,21]. Likewise, higher
levels of IL-10 mRNA transcripts have been found in
untreated coeliac mucosa in vivo when compared to
treated CD patients and controls [2]. Nevertheless, the
ratio between mRNA levels for IL-10 and IFN-γ, as well as
that of FoxP3-expressing cells and IFN-γ, was significantly
lower in untreated and inflamed CD mucosa than in con-
trols. This would suggest that although these high levels of
IL-10 and regulatory T cells reflected a compensatory anti-
inflammatory pathway, it was insufficient to suppress the
overwhelming Th1 mediated response in active CD
[2,19]. In this scenario, immunostimulation triggered by
the intestinal microbiota of active and SFCD patients also
followed the disease features.
PBMC surface phenotype induced by faeces of CD 
patients
Expression of certain surface molecules in PBMCs indi-
cates their maturation level and may predict the quality of
interaction between antigen-presenting cells and T cells
and thereby their activation. Fig 2 shows the results of the
analysis of PBMCs surface antigen expression induced by
faeces from active CD children, SFCD patients and age-Journal of Inflammation 2008, 5:19 http://www.journal-inflammation.com/content/5/1/19
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Cytokine production by peripheral blood mononuclear cells stimulated with faecal samples from active CD patients, symptom  free (SF) CD patients and healthy controls Figure 1
Cytokine production by peripheral blood mononuclear cells stimulated with faecal samples from active CD 
patients, symptom free (SF) CD patients and healthy controls. Panel A, TNF-α production; Panel B, IFN-γ produc-
tion; Panel C, IL-10 production. Results are expressed as mean ± SD of duplicate measurements determined in four independ-
ent experiments. Significant differences between means were established by ANOVA with post hoc Fisher's least significant 
difference (LSD) test at P < 0.05. NS, not significant.
NS
0
500
1000
1500
2000
2500
3000
RPMI LPS Healthy controls CD patients SFCD patients
T
N
F
-
a
l
p
h
a
 
(
p
g
/
m
l
)
 
P<0.001
A
P<0.001 P<0.001
P<0.001
P<0.001
NS
NS NS
0
500
1000
1500
2000
2500
3000
RPMI LPS Healthy controls CD patients SFCD patients
T
N
F
-
a
l
p
h
a
 
(
p
g
/
m
l
)
 
P<0.001
A
P<0.001 P<0.001 P<0.001
P<0.001 P<0.001
P<0.001 P<0.001
NS
 
0
20
40
60
80
100
120
140
160
180
200
RPMI LPS Healthy CD  patients  SFCD  patients
I
F
N
-
g
a
m
m
a
 
(
p
g
/
m
l
)
 
P<0.001
B
P<0.001
P<0.050
NS
P<0.001
P<0.001
0
20
40
60
80
100
120
140
160
180
200
RPMI LPS Healthy CD  patients  SFCD  patients
I
F
N
-
g
a
m
m
a
 
(
p
g
/
m
l
)
 
P<0.001 P<0.001
B
P<0.001
P<0.050 P<0.050
NS NS
P<0.001 P<0.001
P<0.001 P<0.001
 
0
100
200
300
400
500
600
700
800
900
1000
RPMI LPS Healthy  CD patients  SFCD patients
I
L
-
1
0
 
 
(
p
g
/
m
l
)
P<0.050
C
P<0.050
P<0.050
NS
P<0.050 P<0.050
0
100
200
300
400
500
600
700
800
900
1000
RPMI LPS Healthy  CD patients  SFCD patients
I
L
-
1
0
 
 
(
p
g
/
m
l
)
P<0.050 P<0.050
C
P<0.050
P<0.050
NS
P<0.050 P<0.050 P<0.050 P<0.050
 Journal of Inflammation 2008, 5:19 http://www.journal-inflammation.com/content/5/1/19
Page 6 of 13
(page number not for citation purposes)
Expression of surface markers CD4 (Panel A), CD8 (Panel B) and CD86 (Panel C) induced by peripheral blood mononuclear  cells stimulated with faecal samples from active CD patients, symptom-free (SF) CD patients and healthy controls Figure 2
Expression of surface markers CD4 (Panel A), CD8 (Panel B) and CD86 (Panel C) induced by peripheral blood 
mononuclear cells stimulated with faecal samples from active CD patients,  symptom-free (SF) CD patients 
and healthy controls. Results are expressed as mean ± SD of duplicate measurements determined in four independent 
experiments. Significant differences between means were established by ANOVA with post hoc Fisher's least significant differ-
ence (LSD) test at P < 0.05. NS, not significant.
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matched controls. CD4 expression was significantly lower
when PBMCs were stimulated with faeces from active CD
patients than with healthy control samples (P < 0.050; Fig
2A). CD4 expression was also significantly down-regu-
lated when PBMCs were stimulated with samples from
SFCD patients as compared to healthy controls (P < 0.050,
Fig 2A). In contrast, CD8 expression did not differ signifi-
cantly under the effects of faecal samples from the three
groups of children under study (Fig 2B). These results sug-
gest that expression of the co-receptor molecule CD4
could also be under the stimulating effects of the intesti-
nal microbiota in controls and CD patients. In controls,
higher CD4 expression could lead to an increase in the
CD4+ regulatory T cell subpopulation involved in IL-10
production, which is important in maintaining tolerance
to enteric bacteria and dietary antigens [25]. This is in
agreement with the higher production of IL-10 by PBMCs
stimulated with faecal samples from healthy individuals
compared to CD-patient stimulated samples.
In contrast, expression of the co-stimulatory molecule
CD86 increased significantly when PBMCs were stimu-
lated with faeces from both active CD and SFCD patients
(P  < 0.001) compared with healthy controls (Fig 2C).
CD86 expression levels differed after stimulation with the
three faecal-sample types, with the highest to lowest levels
corresponding to active CD faecal samples, followed by
SFCD-patient samples, and healthy control samples,
respectively. Evidently, the intestinal microbiota of both
types of CD patients triggered a higher expression of the
costimulatory molecule CD86, which plays a major role
in initiating immune responses. CD86, together with
CD80 expression on antigen-presenting cells, are essential
for T-cell activation through antigen-specific stimulation,
contributing to Th1 response [28]. Stimulation of mono-
cyte-derived dendritic cell (DC) maturation by microbial
strains or derived products has also been shown to induce
expression of CD86, CD83 and CD40 by both commensal
and pathogenic bacteria [29,30]. However, molecules
involved in activation of Th1 cells were predominantly
expressed on DC exposed to pathogens, parallel to higher
pro-inflammatory cytokine production such as TNF-α
[29]. In general, Gram-negative bacteria have been shown
much more effective in up-regulating maturation markers
of DCs than lactic acid bacteria at lower concentrations
[31]. Gliadin is also known to induce phenotypic and
functional maturation of monocytes, as well as monocyte-
derived DCs [6]. Up-regulation of surface expression of
CD80, CD83, CD86 and CD40 was induced by stimula-
tion of blood mononcytes with gliadin peptides, particu-
larly in combination with IFN-γ [6]. Therefore, this is the
first reported evidence that gut microbiota stimulus,
together with gliadin, could contribute to monocyte mat-
uration, thereby, influencing T-cell interaction and activa-
tion.
Bifidobacteria suppress the pro-inflammatory cytokine 
pattern induced in PBMCs by faeces of CD patients
The  Bifidobacterium  strains included in this study were
selected on the basis of their ability to induce pro- and
anti-inflammatory cytokine production by PBMCs (Fig.
3). Both strains B. longum ES1 and B. bifidum ES2 stimu-
lated the production of significantly higher levels of TNF-
α and IL-10 (P < 0.001; Fig 3A) than non-stimulated cells.
Both strains displayed a similar ability to induce TNF-α
production, as reported in previous comparative studies
[12]. In contrast, B. longum ES1 induced significantly
higher levels (P < 0.050; Fig 3C) of IL-10 production than
B. bifidum ES2 but lower levels (P < 0.050; Fig 3B) of IFN-
γ production. Thus, B. longum ES1 has greater potential to
counteract a Th1-biased response by inducing high pro-
duction of the regulatory cytokine IL10 and low produc-
tion of the Th1 cytokine IFN-γ. Bifidobacterium strains are
generally regarded as less pro-inflammatory than Lactoba-
cillus, more often inducing lower Th1-type cytokine pro-
duction and a T regulatory phenotype based on induction
of high IL-10 production [13,25]. Furthermore, a recent
comparative study of the different immunomodulatory
properties of bifidobacteria has shown that this trait is
strain-dependent, thus different strains can divert
immune response either towards a Th1 pro-inflammatory
or a regulatory profile, highlighting the importance of
careful selection for probiotic applications [12]. The Bifi-
dobacterium strains included in this study also tended to
reduce PBMC surface antigen expression markers, includ-
ing CD4, CD8 and CD86, when used as stimuli, although
effects were not statistically significant (data not shown).
According to our results, none of the probiotic strains of
the VSL#3 product modified CD8 expression in dendritic
cells (DCs) [25]. In contrast, there are previous reports of
Bifidobacterium  species-specific effects on expression of
DC surface markers, demonstrating general increases in
CD86 and CD83 expression [32].
The ability of B. longum ES1 and B. bifidum ES2 strains to
revert the pro-inflammatory cytokine profile induced by
faeces of CD children was also evaluated for potential pro-
biotic applications (Fig. 4). When B. longum ES1 was used
as stimulus together with the faeces of active CD and
SFCD patients, TNF-α (P < 0.001) and IFN-γ (P < 0.001)
production was significantly lower than cytokine levels
produced under exclusive stimulation with both CD
patient faeces (Fig. 4A and 4B). Similar results were
obtained with B. bifidum ES2 (Fig. 4A and 4B). Thus, both
Bifidobacterium stains could counteract the production of
both pro-inflammatory cytokines (TNF-α and IFN-γ) trig-
gered by the altered microbiota, and thus contribute to
normalization of the intestinal inflammatory milieu.
Although  Bifidobacterium  cell suspensions were able to
induce TNF-α when used as unique stimuli, they could
counter-regulate TNF-α production when added togetherJournal of Inflammation 2008, 5:19 http://www.journal-inflammation.com/content/5/1/19
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Cytokine production by peripheral blood mononuclear cells stimulated with live bacteria of Bifidobacterium longum ES1 and B.  bifidum ES2 Figure 3
Cytokine production by peripheral blood mononuclear cells stimulated with live bacteria of Bifidobacterium 
longum ES1 and B. bifidum ES2. Panel A, TNF-α production; Panel B, IFN-γ production; Panel C, IL-10 production. Results 
are expressed as mean ± SD of duplicate measures determined in four independent experiments. Significant differences 
between means were established by ANOVA with post hoc Fisher's least significant difference (LSD) test at P < 0.05. NS, not 
significant.
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Cytokine production by peripheral blood mononuclear cells co-stimulated with faecal samples from either active CD patients  or symptom free (SF) CD patients together with live bacteria of either Bifidobacterium longum ES1 and B. bifidum ES2 Figure 4
Cytokine production by peripheral blood mononuclear cells co-stimulated with faecal samples from either 
active CD patients or symptom free (SF) CD patients together with live bacteria of either Bifidobacterium 
longum ES1 and B. bifidum ES2. Panel A, TNF-α production; Panel B, IFN-γ production; Panel C, IL-10 production. Results 
are expressed as mean ± SD of duplicate measurements determined in four independent experiments. Significant differences 
between means were established by ANOVA with post hoc Fisher's least significant difference (LSD) test at P < 0.05. NS, not 
significant.
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with patient's faeces probably as a result of their interac-
tions or synergic effects with other components present in
faecal samples.
Regulatory IL-10 cytokine production increased signifi-
cantly (P  < 0.050; Fig 4C) by co-stimulation with B.
longum ES1 and B. bifidum ES2 together with faeces of
both patients (Fig. 4C). B. longum ES1 increased IL-10 pro-
duction to a significantly higher extent than B. bifidum ES2
(P < 0.050) according to the data obtained using pure cul-
tures of these strains. This would suggest a more powerful
regulatory role for the former strain. IL-10 plays an impor-
tant role in regulating the inflammatory cascade in the
intestinal mucosa by its action on antigen-presenting cells
via inhibition of cytokine synthesis. IL-10 inhibits the
production of Th1 pro-inflammatory cytokines and par-
ticularly IFN-γ and in turn TNF-α, which is induced by
IFN-γ. Mice genetically deficient in IL-10 develop chronic
enterocolitis caused by an unregulated Th1 response to
endogenous bacterial flora, which could be counteracted
by a strain of Lactococcus lactis secreting recombinant IL-10
[33]. IL-10 administration is also reported to exert benefi-
cial therapeutic effects in Crohn's disease patients by
intravenous administration [34]. In the context of CD,
recombinant human IL-10 has been shown to suppress
Th1-mediated immune responses to gliadin in both
treated and untreated coeliac mucosa via down regulation
of antigen presentation, reduction of T-cell infiltration
and activation, and inducing a long-lasting hyporespon-
siveness in gliadin-specific T cells [2]. However, the clini-
cal usefulness of IL-10 is limited for technical reasons
related to organ-specific delivery and, therefore, a thera-
peutic approach based on probiotic strains triggering IL-
10 production would overcome these limitations and pro-
vide new therapeutic perspectives [35].
B. longum ES1 and B. bifidum ES2 co-incubated with the
faeces of CD patients led to slightly lower expression of
surface markers on PBMCs, particularly in the case of CD4
and CD86. The down-regulatory effects of B. bifidum ES2
seemed to be stronger than those of B. longum ES1 but
none of these differences were statistically significant
(data not shown).
Cytokine production but not PBMC maturation depends 
on NFkB pathway
Cytokine production (TNF-α, IFN-γ, and IL-10) by PBMCs
stimulated with faeces of the three groups of children
under study was completely abolished in the presence of
lactacystin, an inhibitor of the NFκB pathway (data not
shown). TNF-α, IFN-γ and IL-10 production by PBMCs
stimulated by pure cultures of Bifidobacterium strains was
also inhibited on average 33.0% (SD 9.9), 75.0% (SD
18.3) and 50.5% (SD 14.9), respectively, in the presence
of lactacystin (Fig 5). These results indicate that NFκB
pathway is involved in the immune effect of the total
intestinal microbiota, as well as of the tested Bifidobacte-
rium strains. Interaction of the gut microbiota with innate
immune cells through pattern recognition receptors, like
Toll-like receptors (TLRs), is considered to be the starting
point of immunity, sensing the environment and inform-
ing the immunocompetent cells to respond properly to
pathogens or harmless antigens [7]. Common to all TLR is
the activation of NF-κB transcription, leading to upregula-
tion of major histocompatibility complexes and costimu-
latory proteins, as well as production of pro-inflammatory
cytokines and chemokines (TNF-α, IL-1β, and IL-8) and
recruitment of other immune cells. Specific TLRs includ-
ing TLR4, which recognizes LPS from Gram-negative bac-
teria, also activate interferon regulatory factor 3 (IRF3) or
IRF7, leading to the production of type I IFNs, such as
IFNα, that stimulate IFN-γ synthesis [36]. TLR4 and TLR2
mRNA and proteins are up-regulated in the duodenal
mucosa of CD patients with active and non-active disease
compared with controls [37], which could contribute to
amplifying the immune response derived from stimula-
tion by altered intestinal microbiota in these patients. The
NFkB signal transduction pathway is also involved in glia-
din-induced cytokine production by monocytes from CD
patients [6] as well as in increased intestinal permeability
and zonulin production triggered by gliadins in the intes-
tinal epithelium [38].
CD4, CD8 and CD86 expression was slightly reduced by
stimulation with every faecal sample and Bifidobacterium
strains in the presence of lactacystin, but the differences
were not significant (data not shown). This would suggest
that a different activation mechanism, and not the NFκB
pathway, mediates surface antigen expression in the
assayed conditions. By contrast, supernatants of a Bifido-
bacterium breve strain are known to influence maturation
of monocyte-derived dendritic cells by means of NFkB
pathway but not survival and IL-10 production [30].
In summary, this is the first report that the content of the
large intestine of both active and SFCD patients, repre-
senting imbalanced gut microbiota, increases pro-inflam-
matory cytokine production and CD86 activation marker
expression in PBMCs as compared to healthy controls.
Likewise it decreases anti-inflammatory IL-10 cytokine
production, which reflects the Th1 pro-inflammatory
milieu characteristic of CD. Moreover, Bifidobacterium
strains with immunoregulatory properties have been
shown to suppress the pro-inflammatory cytokine pattern
induced by the altered colonic microbiota of CD patients
and strengthen the immune defences of active and SFCD
patients against noxious antigens from the intestinal
lumen. This mechanism of action could complement the
in vitro protective effects exerted by other BifidobacteriumJournal of Inflammation 2008, 5:19 http://www.journal-inflammation.com/content/5/1/19
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Cytokine production by peripheral blood mononuclear cells stimulated with live bacteria of Bifidobacterium longum ES1 and B.  bifidum ES2 in the presence or absence of lactacystin Figure 5
Cytokine production by peripheral blood mononuclear cells stimulated with live bacteria of Bifidobacterium 
longum ES1 and B. bifidum ES2 in the presence or absence of lactacystin. Panel A, TNF-α production; Panel B, IFN-γ 
production; Panel C, IL-10 production. Results are expressed as mean ± SD of duplicate measures determined in four inde-
pendent experiments. Significant differences between means were established by ANOVA with post hoc Fisher's least signifi-
cant difference (LSD) test at P < 0.05. NS, not significant.
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strain against permeability changes induced by gliadin
peptides [39].
Conclusion
The intestinal microbiota of CD patients could contribute
to the Th1 pro-inflammatory milieu characteristic of the
disease, while strains of B. longum and B. bifidum could
reverse these deleterious effects. Thus, the results reported
here offer novel perspectives in the therapy of CD based
on immune modulation by the use of specific probiotic
strains.
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